U.S. Stem Cell
ProfileJobs

U.S. Stem Cell

Suggest Edit
    • Healthbiotechdrug development

    U.S. Stem Cell is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.

    Revenue(FY, 2017)
    $5.5 M
    Type
    Public
    HQ
    Sunrise, US
    Size (employees)
    3 (est)
    Website
    us-stemcell.com
    U.S. Stem Cell is headquartered in Sunrise, US
    Report incorrect company information

    U.S. Stem Cell Office Locations

    U.S. Stem Cell has an office in Sunrise
    Sunrise, US (HQ)
    212 13794 NW 4th St
    Show all (1)
    Report incorrect company information

    U.S. Stem Cell Financials and Metrics

    U.S. Stem Cell Revenue

    Embed Graph
    U.S. Stem Cell's revenue was reported to be $5.52 m in FY, 2017
    USD

    Revenue (Q2, 2018)

    		3.5 m

    Gross profit (Q2, 2018)

    		2.5 m

    Gross profit margin (Q2, 2018), %

    		69.7%

    Net income (Q2, 2018)

    		(1.4 m)

    EBIT (Q2, 2018)

    		(832.6 k)

    Cash (30-Jun-2018)

    		1.7 m
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		96.1 k2.1 m2.2 m3.1 m5.5 m

    Revenue growth, %

    		2040%7%41%

    Cost of goods sold

    		30.8 k844.9 k973 k972 k1.9 m

    Gross profit

    		65.3 k1.2 m1.2 m2.1 m3.6 m
    Quarterly
    USDQ1, 2018Q2, 2018

    Revenue

    		1.7 m3.5 m

    Cost of goods sold

    		503.8 k1.1 m

    Gross profit

    		1.2 m2.5 m

    Gross profit Margin, %

    		71%70%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2017

    Cash

    		46.2 k36.7 k58.4 k986.8 k

    Accounts Receivable

    		43 k

    Inventories

    		70.4 k

    Current Assets

    		66.9 k141.3 k115.6 k1.1 m
    Quarterly
    USDQ1, 2018Q2, 2018

    Cash

    		1.7 m1.7 m

    Accounts Receivable

    		75.9 k47.4 k

    Inventories

    		76.7 k66.1 k

    Current Assets

    		1.9 m1.8 m
    show all
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(3.1 m)(2.3 m)(1.6 m)(2.1 m)(3.5 m)

    Depreciation and Amortization

    		2.2 k4.5 k5.3 k5.8 k178.7 k

    Inventories

    		(28.1 k)

    Accounts Payable

    		469.2 k
    show all
    USDY, 2018

    Financial Leverage

    		-0.3 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Forge Therapeutics
    Health - Private
    Lodo Therapeutics
    Health - Private
    Vital Therapies
    Health - Public
    Frequency Therapeutics
    Health - Private
    Compare competitors

    U.S. Stem Cell Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    U.S. Stem Cell Company Life and Culture

    Report incorrect company information
    Download PDF